Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085436 · ClinicalTrials.gov registry record · Phase 2
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
A Phase 2 study of Kidney Cancer, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00085436 is a Phase 2 study of Kidney Cancer that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 18 participants, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00085436, a Phase 2 study of Kidney Cancer, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's lymphocytes to kill kidney cancer cells. Interferon alfa may interfere with the growth of cancer cells. Combining vaccine therapy with interleukin-2 and interferon alfa may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving vaccine therapy together with interleukin-2 and interferon alfa works in treating patients with metastatic renal cell carcinoma (kidney cancer).
Conditions Studied
Interventions
- BIOLOGICAL recombinant interferon alfa
- BIOLOGICAL autologous tumor cell vaccine
- BIOLOGICAL Aldesleukin,
Study Locations (1)
New Hampshire
- Norris Cotton Cancer Center at Dartmouth - Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2003-12 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00085436
The ClinicalTrials.gov registry entry for NCT00085436 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Cancer appearing as the primary indexed condition, and to 3 interventions - of which recombinant interferon alfa is the first listed.
NCT00085436 reports 1 study location spanning 1 distinct geographic area - top geographies include New Hampshire.
Frequently Asked Questions
What is clinical trial NCT00085436 about?
NCT00085436 is a clinical study titled "DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC". RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's lymphocytes to kill kidney cancer cells. Interferon alfa may interfere with the growth of cancer cells. Combining vaccine t...
What is the current status of trial NCT00085436?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2003-12. Estimated completion is 2009-10.
What conditions does trial NCT00085436 study?
This clinical trial studies the following conditions: Kidney Cancer.
What interventions are being tested in trial NCT00085436?
The interventions under investigation include: recombinant interferon alfa (BIOLOGICAL), autologous tumor cell vaccine (BIOLOGICAL), Aldesleukin, (BIOLOGICAL).
Who is sponsoring clinical trial NCT00085436?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00085436 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
NSAID Use After Robotic Partial Nephrectomy
RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
RECRUITING · Phase 2
-
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RECRUITING · Phase 2
-
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.